PharmacyCodes



Trandolaprilum [Latin] en es it fr

Trandolaprilum [Latin] Brand names, Trandolaprilum [Latin] Analogs

Trandolaprilum [Latin] Brand Names Mixture

  • No information avaliable

Trandolaprilum [Latin] Chemical_Formula

C20H27NO3

Trandolaprilum [Latin] RX_link

No information avaliable

Trandolaprilum [Latin] fda sheet

Trandolaprilum [Latin] msds (material safety sheet)

Trandolaprilum [Latin] Synthesis Reference

No information avaliable

Trandolaprilum [Latin] Molecular Weight

329.433 g/mol

Trandolaprilum [Latin] Melting Point

264 oC

Trandolaprilum [Latin] H2O Solubility

No information avaliable

Trandolaprilum [Latin] State

Solid

Trandolaprilum [Latin] LogP

2.635

Trandolaprilum [Latin] Dosage Forms

Capsules

Trandolaprilum [Latin] Indication

Used in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.

Trandolaprilum [Latin] Pharmacology

Trilostane blocks an enzyme involved in the production of several steroids including cortisol. Inhibiting this enzyme inhibits the production of cortisol. In Cushing's syndrome, the adrenal gland overproduces steroids. Although steroids are important for various functions of the body, too much can cause problems. Trilostane reduces the amount of steroids produced by the adrenal gland. This product was withdrawn from the U.S. market in April 1994.

Trandolaprilum [Latin] Absorption

No information avaliable

Trandolaprilum [Latin] side effects and Toxicity

Symptoms of overdose include darkening of skin, drowsiness or tiredness, loss of appetite, mental depression, skin rash, and/or vomiting.

Trandolaprilum [Latin] Patient Information

No information avaliable

Trandolaprilum [Latin] Organisms Affected

Humans and other mammals